Last 4,468 GBp
Change Today -27.00 / -0.60%
Volume 1.5M
SHP On Other Exchanges
Symbol
Exchange
SHP is not on other exchanges.
As of 11:35 AM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHP) Snapshot

Open
4,497 GBp
Previous Close
4,495 GBp
Day High
4,549 GBp
Day Low
4,454 GBp
52 Week High
10/6/14 - 5,470 GBp
52 Week Low
12/6/13 - 2,620 GBp
Market Cap
26.3B
Average Volume 10 Days
1.8M
EPS TTM
3.19 GBp
Shares Outstanding
589.6M
EX-Date
09/3/14
P/E TM
22.0x
Dividend
12.45 GBp
Dividend Yield
0.28%
Current Stock Chart for SHIRE PLC (SHP)

shire plc (SHP) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc (SHP) Top Compensated Officers

Managing Director, Chief Executive Officer an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc (SHP) Key Developments

Shire plc Presents at Credit Suisse Annual Healthcare Conference, Nov-12-2014 03:30 PM

Shire plc Presents at Credit Suisse Annual Healthcare Conference, Nov-12-2014 03:30 PM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: Flemming Ornskov, Managing Director, Chief Executive Officer and Director.

Shire plc Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 12:55 PM

Shire plc Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 12:55 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Sam Rasty.

Shire plc Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014 and for the Year 2014

Shire plc announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $1,597.1 million against $1,212.7 million a year ago. Operating income from continuing operations was $572.0 million against $382.9 million a year ago. Income from continuing operations before income taxes and equity in earnings of equity method investees was $575.6 million against $374.8 million a year ago. Income from continuing operations, net of tax was $515.8 million or 87.0 cents per diluted share against $301.1 million or 52.7 cents per diluted share a year ago. Net income was $479.7 million or 80.9 cents per diluted share against $278.2 million or 48.8 cents per diluted share a year ago. Net cash provided by operating activities was $593.4 million against $433.7 million a year ago. Purchases of PP&E were $30.7 million against $45.3 million a year ago. Non GAAP operating income was $716.5 million against $448.9 million a year ago. Non GAAP net income from continuing operations was $579.6 million against $350.2 million a year ago. Non GAAP net income was $579.6 million against $350.2 million a year ago. Non GAAP diluted earnings per ADS was 293.4 cents against 183.3 cents a year ago. Non GAAP EBITDA was $760.2 million against $481.3 million a year ago. Non GAAP cash generation was $611.8 million against $481.8 million a year ago. For the nine months, the company reported total revenues of $4,446.0 million against $3,608.3 million a year ago. Operating income from continuing operations was $1,216.8 million against $1,135.2 million a year ago. Income from continuing operations before income taxes and equity in earnings of equity method investees was $1,228.7 million against $1,107.7 million a year ago. Income from continuing operations, net of tax was $1,297.2 million or 87.0 cents per diluted share against $873.0 million or 52.7 cents per diluted share a year ago. Net income was $1,233.2 million or 219.1 cents per diluted share against $601.1 million or 152.5 cents per diluted share a year ago. Net cash provided by operating activities was $1,673.5 million against $852.7 million a year ago. Non GAAP operating income was $1,937.5 million against $1,349.3 million a year ago. Non GAAP net income from continuing operations was $1,569.3 million against $1,039.1 million a year ago. Non GAAP net income was $1,569.3 million against $1,061.8 million a year ago. Non GAAP diluted earnings per ADS was 795.0 cents against 542.1 cents a year ago. Non GAAP EBITDA was $2,062.7 million against $1,438.6 million a year ago. Non GAAP cash generation was $1,601.7 million against $1,113.3 million a year ago. Net debt, also a Non GAAP measure, was $396 million at September 30, 2014 against $2,231 million at December 31, 2013. For the fourth quarter, the company anticipates product sales growth to be lower than delivered so far in 2014, as the third quarter benefited from Rare Diseases sales to customers who order less frequently and as the company lap against stronger comparatives in the fourth quarter. The company expects slightly higher operating costs than seen in the third quarter, as it continues to invest behind innovative and exciting pipeline. For 2014, the company expects to deliver Non GAAP earnings per ADS growth in the high 30% range in 2014 compared to previous guidance of low-to-mid 30% growth. Following strong product sales performance in the year to date, the company now expects product sales growth for the full year 2014 in the low 20% range compared to previous guidance of high teens growth. Non GAAP gross margin will be approximately 1% point lower than in 2013. Combined Non GAAP R&D and SG&A to grow by 2-4% compared to 2013. Non GAAP net interest expense is to be approximately $10 million lower than in 2013. Core effective tax rate on Non GAAP income is still expected to be in the range of 17-19%. Current assumption of the diluted number of ordinary shares for full year 2014 is approximately 590 million. Royalties and other revenues for 2014 to be 0-5% lower than in 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 4,468.00 GBp -27.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $212.10 USD +0.29
Astellas Pharma Inc ¥1,713 JPY -9.50
CSL Ltd A$80.35 AUD +0.85
Mylan Inc/PA $56.17 USD +0.21
Valeant Pharmaceuticals International Inc C$162.85 CAD +1.83
View Industry Companies
 

Industry Analysis

SHP

Industry Average

Valuation SHP Industry Range
Price/Earnings 22.6x
Price/Sales 7.1x
Price/Book 6.3x
Price/Cash Flow 31.8x
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.